Skip to main content

Security report for biogen-sa.com

Biogen · Healthcare · Saudi Arabia

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

80/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen is a globally recognized biotechnology company specializing in innovative therapies for complex neurological and rare diseases. The Saudi Arabia localized website reflects the company's commitment to serving regional audiences with tailored content and resources. The site highlights Biogen's leadership in treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, positioning it as a key player in the healthcare sector. Technically, the website leverages Adobe Experience Manager CMS, integrates modern analytics and consent management tools, and demonstrates good mobile optimization and user experience. Security posture is solid with HTTPS enforcement and cookie consent mechanisms, though lacks published security policies and incident response contacts. The absence of WHOIS registration data is a notable concern, suggesting the need for further domain legitimacy verification. Overall, the website is professional, content-rich, and trustworthy, serving its target audience effectively while maintaining compliance with privacy regulations.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen-sa.com

This scan found 17 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
67
Security headers
95
Email security
60
DNS health
75
Network security
100
GDPR outside view
83
Average
80

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen operates in the healthcare biotechnology sector with a strong market position supported by a portfolio of breakthrough medicines. The business model focuses on research, development, and commercialization of therapies for neurological and rare diseases. The website targets healthcare professionals, patients, and stakeholders in Saudi Arabia, indicating a regional market focus. The presence of multiple country-specific domains and partner sites suggests a broad international footprint with localized operations. The company emphasizes innovation, responsibility, and career opportunities, reflecting a mature and growth-oriented organization. Strategic partnerships and regional sites enhance market penetration and customer engagement. The lack of direct contact details on the site may indicate a preference for controlled communication channels.

Security posture

The website demonstrates a good security baseline with HTTPS enabled and use of secure cookies (httpOnly). Cookie consent is managed via Cookiebot, ensuring compliance with privacy laws. However, the absence of explicit security policies, incident response information, and vulnerability disclosure mechanisms indicates gaps in transparency and preparedness. No security headers were detected in the provided data, suggesting room for improvement in defense-in-depth strategies. No vulnerabilities or exposed sensitive data were observed. Overall, the security posture is adequate for a corporate website but could be enhanced by publishing security documentation and implementing additional HTTP security headers.

Recommendations

  1. Publish a comprehensive security policy and incident response contact information on the website.
  2. Implement and configure HTTP security headers such as Content-Security-Policy, X-Frame-Options, and Strict-Transport-Security.
  3. Establish and publicize a vulnerability disclosure program or security.txt file to encourage responsible reporting.
  4. Enhance accessibility features to meet recognized standards and improve user inclusivity.
  5. Verify and update WHOIS registration details to ensure domain legitimacy and transparency.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen
Description
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
Key services
Development and commercialization of medicines for multiple sclerosis, Treatment for spinal muscular atrophy, Treatments addressing Alzheimer's disease pathology
Content quality
good
Branding
consistent

Technology

Stack
Adobe Helix RUM, jQuery 3.6.4, Cookiebot, Google Tag Manager, Google Analytics, Video.js
Frameworks
Adobe Experience Manager (AEM)
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent banner with opt-in/out
  • Use of httpOnly cookies for security
  • Load balancing cookies for performance

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Content is professionally presented and relevant to biotechnology and healthcare.
  3. Cookie consent and privacy policies are implemented and accessible.
  4. WHOIS data is missing or unavailable, which is unusual for a corporate domain.
  5. No direct contact emails or phone numbers found; contact is via forms.
  6. Social media links point to official Biogen accounts.
  7. Website uses modern technologies and Adobe Experience Manager CMS.
  8. No security policy or incident response information published.
  9. No vulnerability disclosure or security.txt file detected.
Technical notes

Notes

The website is built on Adobe Experience Manager, a robust enterprise CMS platform, indicating a mature digital infrastructure. It uses modern JavaScript libraries including jQuery 3.6.4 and integrates Google Tag Manager and Google Analytics for tracking and analytics. Cookiebot is employed for cookie consent management, reflecting privacy compliance efforts. The site includes multimedia content with Video.js for video playback. Performance is moderate with good mobile responsiveness and SEO optimization. Some scripts are loaded with type 'text/plain' likely for consent management purposes. No hosting provider details were identified. Overall, the technical implementation supports a professional and scalable web presence but could benefit from enhanced accessibility and security header configurations.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen-sa.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen-sa.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.